Guest Editors:
Professor Charlotte Teunissen, PhD, Amsterdam UMC, the Netherlands
Everard (Jort) Vijverberg, MD, PhD, Amsterdam UMC, the Netherlands
Alzheimer's Research & Therapy is calling for submissions to our Collection on Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders.
In Alzheimer’s disease (AD), microglia surround extracellular plaques and mount a sustained inflammatory response, contributing to the pathogenesis of the disease. Identifying approaches to specifically target...
Aberrant neuronal Sigma-1 receptor (Sig-1r)-mediated endoplasmic reticulum (ER)- mitochondria signaling plays a key role in the neuronal cytopathology of Alzheimer’s disease (AD). The natural psychedelic N, N-...
The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer’s and Parkinson’...
Functional connectivity (FC) biomarkers play a crucial role in the early diagnosis and mechanistic study of Alzheimer’s disease (AD). However, the identification of effective FC biomarkers remains challenging....
Cardiovascular health has been associated with dementia onset, but little is known about the variation of such association by sex and age considering dementia subtypes. We assessed the role of sex and age in t...
Studies have suggested that blood circulating phytosterols, plant-derived sterols analogous to cholesterol, were associated with blood lipid levels and the risk of Alzheimer’s disease (AD) and Parkinson’s dise...
GOIZ ZAINDU (“caring early” in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evalua...
Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ ol...
Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the initial...
Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed important cellular and functional features of Alzheimer's disease (AD), a prevalent neurodegenerative disease. However, our knowledge regardi...
Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...
NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...
The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...
Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...
Little is known about the associations of midlife- and late life-initiated walking with Alzheimer’s disease (AD)-related cognitive decline in humans. We aimed to investigate whether high-intensity, prolonged, ...
The scientific field of neurodegenerative dementias has made significant progress over the last two decades. The diagnosis for these progressive neurodegenerative diseases is increasingly shifting from syndromal, based on signs and symptoms, to a biological construct based on the pathological hallmarks. For Alzheimer's disease (AD) it is amyloid β deposition, pathologic tau, neurodegeneration, and it is expected that analysis of alfa-synuclein (e.g. by aggregating assays) can contribute to an accurate diagnosis and to define progression and treatment effects. Furthermore, numerous genetic risk factors have been identified providing further insight into the pathways underpinning dementias.
Analogous to this significant progress in making an accurate diagnosis and a better understanding in dementia disorders, the drug development landscape for disease modifying therapies also grows. Especially in AD, amyloid-targeting therapies are now showing potential, while it is clear that multitarget interventions are probably needed to better silence these diseases. Moreover, drugs against targets that play a key role in several neurodegenerative diseases can be applied across diseases.